Trial Profile
A Phase III Randomized Trial Investigating Bortezomib (NSC 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Jan 2024
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Cytarabine; Daunorubicin; Dexamethasone; Dexamethasone; Doxorubicin; Etoposide; Folinic acid; Folinic acid; Hydrocortisone; Ifosfamide; Mercaptopurine; Methotrexate; Methotrexate; Methotrexate; Pegaspargase; Tioguanine; Vincristine
- Indications Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 12 Dec 2023 Results from AALL0434 and AALL1231 , presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 26 Sep 2023 Planned End Date changed from 22 Sep 2023 to 22 Sep 2024.
- 15 Jun 2023 Results investigating whether high immunoproteasome (iP) activity is correlated with BTZ-sensitivity presented at the 28th Congress of the European Haematology Association